Effects of ACEI on Bone Turnover

Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02377440

Enrollment

Registered

2015-03-03

Start date

2013-10-31

Completion date

2015-12-31

Last updated

2015-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Turnover Status in Hypertensive Patients

Keywords

ACE inhibitor

Brief summary

The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* at least 45 years of age * a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control * able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment).

Exclusion criteria

* younger than 45 years of age * a diagnosis of metabolic bone disease * a diagnosis of osteoporosis or use of medication to treat osteoporosis * a diagnosis of diabetes mellitus, or renal insufficiency, or cancer * history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.

Design outcomes

Primary

Measure	Time frame
Change in serum CTX levels in pg/mL	baseline, 3 months

Countries

United States

Outcome results